Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity chemoradiation for early anal canal cancer
ACTRN12610000188033Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Mar 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of fluorouracil and mitomycin c in anal squamous cell carcinoma (SCCA), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: 5-year colostomy-free survival and Late toxicity. Started Mar 1999; status: completed.
02
Drugs
fluorouracilmitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on ACTRN12610000188033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000188033.